Table 1.
Comparison of in vitro and in vivo efficacies of existing antiviral agents against SARS CoV-2 from the published literature.a.
| Drug | In-vivo study and trial result | In-vitro study result |
|---|---|---|
| Lopinavir/ritonavir** | Not efficient [122] Trial results awaited [27] |
Anti-SARS CoV-2 activity reported at concentration of LPV- 7 μg/mL and RTV- 1.75 μg/mL [24] |
| Oseltamivir** | Not efficient [34] Trial results awaited [39] |
Not efficient [35,36] |
| Zanamivir | Anti-SARS CoV-2 activity reported [45] | Not efficient [36] |
| Peramivir | Not efficient [23,47] | Not efficient [23,47] |
| Remdesivir | Anti-SARS CoV-2 activity reported [55,57] | Anti-SARS CoV-2 activity was reported in Vero E6 cells at 1.76 μM concentration [97] |
| Ribavirin** | Anti-SARS CoV-2 activity reported [71] Trial results awaited [[67], [68], [69], [70]] |
NA |
| Darunavir** | Not efficient [79,80] Trial results awaited [78] |
Anti-SARS CoV-2 activity at a concentration of 300 μM [77] |
| Umifenovir*** | Anti-SARS CoV-2 activity reported [89] | Anti-SARS CoV-2 activity at a concentration of 21–36 μM [123] |
| Favipiravir* | Anti-SARS CoV-2 activity reported [100,101] | Anti-SARS CoV-2 activity at a concentration of around 400 μM [97] |
| Amantadine** | Anti-SARS CoV-2 activity reported [110] Trial results awaited [111,112] |
Anti-SARS CoV-2 activity at a concentration of 83–119 μM [109] |
| Molnupiravir** | Anti-SARS CoV-2 activity reported [117,118] Trial results awaited [119,120] |
Anti-SARS CoV-2 activity at a concentration of 3.4 μM and 5.4 μM [117]. |
a
* trials completed; ** trials underway still; *** trials contradictory.